The clinical significance of the promoter methylation of CDH13 gene in bladder cancer

Abstract

Objectives The aim of this study was to investigate the clinical significance of the promoter methylation of CDH13 gene in bladder cancer.Methods The promoter methylation of CDH13 gene in 23 normal bladder mucosa and 71 bladder transitional cell carcinoma tissues was detected using methylation specific polymerase chain reaction (MSP),and correlated with clinicopathological data of bladder cancer patients.Results The methylation rate CDH13 gene in 71 bladder transitional cell carcinoma tissues was 60.6％,however no methylation was found in 23 normal bladder mucosa tissues,and the difference was statistically significant (P ＜ 0.01).The promoter methylation of CDH13 gene in bladder transitional cell carcinoma tissues was unrelated with patient's age,gender,tumor number or tumor shape (P ＞ 0.05),but correlated with tumor growth,poor differentiation and tumor invasion(P ＜ 0.05).Conclusions The promoter methylation is closely correlated with the occurrence and development of bladder cancer,and which may be used as a potential biomarker for the early diagnosis,monitoring and prognosis of bladder cancer. Key words: Urinary Bladder Neoplasms; Promoter Regions (Genetics) ; Methylation